Study Summary
This trial is testing a new type of cancer treatment involving genetically modified immune cells.
- Ovarian Cancer
- Primary Peritoneal Carcinoma
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 4 Secondary · Reporting Duration: 15 years
Trial Safety
Safety Progress
Trial Design
4 Treatment Groups
Cohort 3: MOv19-BBz CAR T cells after chemo
1 of 4
Cohort-1: without chemo;only if dose de-escalation required
1 of 4
Cohort 1: MOv19-BBz CAR T cells without chemo
1 of 4
Cohort 2: MOv19-BBz CAR T cells after chemo
1 of 4
Experimental Treatment
18 Total Participants · 4 Treatment Groups
Primary Treatment: MOv19-BBz CAR T cells · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · Female Participants · 9 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are participants currently being enrolled in this research?
"As per the details provided on clinicaltrials.gov, this research is currently enrolling individuals into its study group. The trial was initially posted in October 2018 and has recently been updated as of September 2022." - Anonymous Online Contributor
Has the FDA granted approval to MOv19-BBz CAR T cells?
"MOv19-BBz CAR T cells have limited clinical data to support their safety and efficacy, so they were assigned a score of 1." - Anonymous Online Contributor
What is the sample size of participants enrolled in this experiment?
"Affirmative. According to the data hosted on clinicaltrials.gov, this medical trial is actively recruiting patients that were first mentioned in October 2018 and recently updated in September 2022. The study requires 18 individuals from 1 centre for participation." - Anonymous Online Contributor